GB Sciences, Inc. (GBLX)
OTCMKTS
· Delayed Price · Currency is USD
0.0009
+0.0001 (12.50%)
Mar 14, 2025, 4:00 PM EST
GB Sciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
366.36K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.18B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
BioStem Technologies | 210.49M |
GB Sciences News
- 2 years ago - Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform - GlobeNewsWire
- 2 years ago - Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations - GlobeNewsWire
- 2 years ago - Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit - GlobeNewsWire
- 2 years ago - Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference - GlobeNewsWire
- 2 years ago - Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article - GlobeNewsWire